Probiodrug to present data on therapeutic concept of targeting pyro-Glu Abeta and its frontrunner QC-inhibitor PQ912 at International Alzheimer Conferences
Posted: 17 November 2014 | | No comments yet
Probiodrug AG, a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s Disease, announces that Prof. Hans-Ulrich Demuth, co- founder and consultant of Probiodrug, will be reviewing the target validation and summarize data on its lead product candidate PQ912 at two international conferences…
Probiodrug AG (“Probiodrug”), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s Disease, announces that Prof. Hans-Ulrich Demuth, co- founder and consultant of Probiodrug, will be reviewing the target validation and summarize data on its lead product candidate PQ912 at two international conferences.
The presentation and poster entitled ‘Inhibitors of glutaminyl cyclase (QC) which is up-regulated early in Alzheimer’s Disease (AD) block toxic pGlu-Abeta formation, are safe in early clinics’ will be presented at:
(1) Society for Neuroscience 44th annual meeting, Neuroscience 2014 Meeting in Washington DC
Session: Aggregation of Amyloid, Tau, and Other Proteins on 18th November at 9:30am to 9:45am EST
(2) 7th annual Clinical Trials on Alzheimer’s Disease (CtaD) in Philadelphia
Late Breaking Poster Session P1-38 on 20th November.
